GlaxoSmithKline has created a new chief digital and technology officer role as it seeks to transform how new technologies are used to improve the entire group’s performance.
The role will be filed by Karenann Terrell, who will join the pharma firm on 4 September and take up a seat on its Corporate Executive Team.
Emma Walmsley, GSK’s chief executive officer, said: “The impact of technology on the healthcare industry is accelerating and requires us to rethink our approach.
“As a member of the Executive Team, Karenann will have the scope to think radically about how we can exploit the latest opportunities and ultimately improve our business performance.”
GSK has consistently been active in the digital space, most recently looking to apply artificial intelligence to drug discover, targeting COPD adherence with sensor technology and rolling out its first medical device mobile app. However, new CEO Walmsley clearly wants more to be done when it comes to the bigger picture of applying digital technologies.
Terrell previously spent six years as chief information officer for Walmart, where she led a multi-year effort to transform the US retail giant’s use of data, analytics and digital customer engagement.
She will also bring pharma experience to the role, having spent four years before her time at Walmart serving as chief information officer for Baxter International.
In this new role at GSK, Terrell will be responsible for developing GSK’s digital, data and analytics strategy and will work with a wide range of partners from inside and outside the healthcare sector to bring new technologies to GSK.
Her aim will be to enhance areas such as clinical trials and drug development and improve the way GSK interacts with healthcare professionals, customers and consumers, as well as making internal processes more efficient.
Commenting on Terrell’s appointment last week GSK’s CEO Emma Walmsley said she would be “a key partner to accelerate and modernise our capabilities here”.
